原创首发 | 金角财经(ID: F-Jinjiao)作者 |田羽在经历了营收、利润双降的2024年后,白云山终于在2025年三季报中交出一份“止跌”的成绩单。今年前三季度,这家中药龙头实现营收616.06亿元,同比增长4.31%;归母净利润33.1亿元,同比增长4.78%。乍一看,总算止住了下滑的势头。但仔细拆开数据,这份“增长”更多来自于去年的低基数。放在更长周期看,白云山的利润水平依旧低于...
Source Link原创首发 | 金角财经(ID: F-Jinjiao)作者 |田羽在经历了营收、利润双降的2024年后,白云山终于在2025年三季报中交出一份“止跌”的成绩单。今年前三季度,这家中药龙头实现营收616.06亿元,同比增长4.31%;归母净利润33.1亿元,同比增长4.78%。乍一看,总算止住了下滑的势头。但仔细拆开数据,这份“增长”更多来自于去年的低基数。放在更长周期看,白云山的利润水平依旧低于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.